Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements
I'm PortAI, I can summarize articles.
Analyst Rami Katkhuda from LifeSci Capital maintains a Buy rating on Amylyx Pharmaceuticals, with a $24.00 price target, due to promising Phase I LUMINA study results. The study shows AMX0114 is well-tolerated with no serious adverse events, and its specificity in inhibiting calpain-2 offers therapeutic advantages. Strategic plans to advance to the second cohort and anticipated biomarker data in 2026 further support the Buy rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments